BioSpace News Archive

BIOXYTRAN, INC. announced the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor.

The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases.

Phio Pharmaceuticals Corp. announced that the United States Patent and Trademark Office has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231.

N4 Pharma PLC (AIM: N4P), the pre-clinical stage specialist pharmaceutical company, recently acquired a controlling interest in Nanogenics Limited. Nanogenics has developed a lipid and peptide-based delivery system, LipTide®, which it is using in the formulation of a novel siRNA product – ECP105 – targeting an unmet clinical need in the ophthalmology market.

Ambrx Biopharma, Inc., announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.

AB Science SA announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the fourth quarter and full year ended December 31, 2023.

Lipocine Inc. today announced that Dr. Mahesh V. Patel , President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference.

AbbVie and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.